硼替佐米为主化疗方案治疗多发性骨髓瘤患者临床疗效及生存影响因素分析

doi:10.3969/j.issn.1006-6233.2020.07.031

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1297 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical efficacy of bortezomib-based chemotherapy regimen in the treatment of multiple myeloma (MM) and to analyze the related factors affecting the prognosis of patients. Methods: The clinical data of 80 patients with MM who received bortezomib-based chemotherapy regimen were retrospectively analyzed. The efficacy was evaluated, and Kaplan-Meier method was used for survival analysis, and the 3-year overall survival (OS) rate and progression-free survival (PFS) rate were estimated. Log-rank test and Cox proportional hazard regression model were used for univariate analysis and multivariate analysis on factors that might affect prognosis. Results: Of the 80 patients, the total effective rate was 82.5% and the CR rate was 43.8%. The median follow-up time was 28 (2~89) months, and the 3-year OS of the whole group was 76.4%, and the PFS rate was 57.8%. Univariate analysis showed that prognosis of MM patients was related to age, ISS staging, white blood cell count, homocysteine (Hcy) level, platelet count (PLT), lactate dehydrogenase level, Kappa light chain level, FISH results, efficacy and presence or absence of HSCT treatment (P<0.05), and was not related to gender, DS staging, hemoglobin level, serum creatinine level, urea nitrogen level, bone marrow plasma cell number, MM type, albumin, chromosome condition, bone damage and kidney damage (P>0.05). Cox multivariate analysis showed that PLT≤100×10⁹L^-1, Hcy≥22μmol/L and Kappa light chain level≥19.4mg/L were independent risk factors for the prognosis (OS and PFS) of MM patients (P<0.05), and efficacy ≥ VGPR was a beneficial factor for prognosis (OS) (P<0.05). Conclusion: Bortezomib-based chemotherapy regimen has significant efficacy in the treatment of MM. PLT, Hcy and Kappa light chain level are independent risk factors for survival of patients, and efficacy ≥ VGPR is a beneficial factor for survival.

Key words： Multiple myeloma Bortezomib Chemotherapy Efficacy Survival time Influencing factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.07.031 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I7/1186

[1] 刘巍峰,王涛,李远,等.多发性骨髓瘤骨病的外科治疗及预后因素[J].中华骨科杂志,2018,38(14):841~850.
[2] Migkou M, Gavriatopoulou M, Terpos E,et al. Optimizing therapy in bortezomib-exposed patients with multiple myeloma[J]. Expert Rev Hematol, 2018, 11(6):463~469.
[3] 蔡小会.束化干预策略对硼替佐米治疗多发性骨髓瘤致相关周围神经病变患者的影响[J].现代中西医结合杂志,2019,28(33):3753~3755.
[4] 王珣,徐岚,赵素芳,等.硼替佐米腹部皮下注射治疗多发性骨髓瘤的疗效及不良反应的护理[J].中华现代护理杂志,2018,24(12):1450~1453.
[5] Zafar M S H, Khan A A, Aggarwal S,et al. Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma[J]. South Asian Cancer, 2018, 7(1):58~60.
[6] 翟勇平,陈兵,于亮.《中国多发性骨髓瘤诊治指南(2015年修订)》治疗部分江苏解读[J].医学研究生学报,2016,29(10):1014~1019.
[7] Kyle RA,Rajkumar SV.Criteria for diagnosis,staging,risk stratification and response assessment of multiple myeloma[J].Leukemia,2014,28(4):3~9.
[8] 王得印,郝云良,肖萌,等.多发性骨髓瘤流行病学及病因分析[J].国际流行病学传染病学杂志,2018,45(4):277~280.
[9] 周静静,冯献启,聂淑敏,等.免疫表型对以硼替佐米为主方案治疗的多发性骨髓瘤患者预后的影响[J].白血病·淋巴瘤,2018,27(8):459~463.
[10] Wu C K,Yang A H,Lai H C,et al.Combined proximal tubulopathy,crystal-storing histiocytosis,and cast nephropathy in a patient with light chain multiple myeloma[J].BMC Nephrol,2017,18(1):170~174.
[11] 戴兰,何林燕,沈文红,等.十色流式细胞术在多发性骨髓瘤诊断及治疗监测中的意义[J].中国血液流变学杂志,2018,26(3):250~253.
[12] 孙巨勇,牟娜,牟佳,等.中性白细胞/淋巴细胞比例和血小板/淋巴细胞比例变化在多发性骨髓瘤患者中的意义[J].中国实验血液学杂志,2019,27(4):214~218.